Literature DB >> 1934462

Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy.

J Grevel1, B D Kahan.   

Abstract

Abbreviated kinetic profiles can reduce the number of phlebotomies and drug assays, and thereby the cost of area-under-the-curve (AUC) monitoring. In the present investigation, we used two independent data sets: group 1, 101 AUC profiles from 77 stable renal-transplant patients, which included a 5-h sample in addition to the usual 0-, 2-, 4-, 6-, 10-, 14-, and 24-h samples; and group 2, 100 profiles from 50 stable renal-transplant patients before and after a change in their daily oral dose of cyclosporine. Group I demonstrated a fair correlation between cyclosporine trough concentrations and the AUC calculated from a complete set of seven concentrations (r2 = 0.820 and 0.758 for the 24- and 0-h samples, respectively). Stepwise multiple linear-regression analysis revealed that the abbreviated set of three time points (2, 6, and 14 h) explained 96% of the variance in AUC values calculated from the full set of seven samples; additional time points increased the accuracy only slightly. For group 2, we examined the difference between the observed and the predicted concentrations by linear extrapolation; the error in the observed AUC value, compared with the predicted value calculated from seven time points (-13.2% to -1.2%), was similar to the error from just three time points (-11.5% to 4.5%). Abbreviated AUC profiles involving three time points used with a model equation seem to provide a reliable alternative to full seven-point profiles.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934462

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 3.  Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.

Authors:  Caroline Monchaud; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  Development of limited sampling strategies for characteristics of a pharmacokinetic profile.

Authors:  W M Sallas
Journal:  J Pharmacokinet Biopharm       Date:  1995-10

5.  Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.

Authors:  Franziska Schädeli; Hans-Peter Marti; Felix J Frey; Dominik E Uehlinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Concentration-controlled trials. What does the future hold?

Authors:  A Johnston; D W Holt
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 7.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 8.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

9.  Comparison of architect I 2000 for determination of cyclosporine with axsym.

Authors:  Nafija Serdarevic; Lejla Zunic
Journal:  Acta Inform Med       Date:  2012-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.